Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.

Bonifazi F, Solano C, Wolschke C, Sessa M, Patriarca F, Zallio F, Nagler A, Selleri C, Risitano AM, Messina G, Bethge W, Herrera P, Sureda A, Carella AM, Cimminiello M, Guidi S, Finke J, Sorasio R, Ferra C, Sierra J, Russo D, Benedetti E, Milone G, Benedetti F, Heinzelmann M, Pastore D, Jurado M, Terruzzi E, Narni F, Völp A, Ayuk F, Ruutu T, Kröger N.

Lancet Haematol. 2019 Feb;6(2):e89-e99. doi: 10.1016/S2352-3026(18)30214-X.

PMID:
30709437
2.

Eltrombopag for post-transplant cytopenias due to poor graft function.

Marotta S, Marano L, Ricci P, Cacace F, Frieri C, Simeone L, Trastulli F, Vitiello S, Cardano F, Pane F, Risitano AM.

Bone Marrow Transplant. 2019 Jan 24. doi: 10.1038/s41409-019-0442-3. [Epub ahead of print]

PMID:
30679824
3.

Stem cell transplantation for congenital dyserythropoietic anemia. An analysis from the European society for blood and marrow transplantation.

Miano M, Eikema DJ, Aljurf M, Van't Veer PJ, Öztürk G, Wölfl M, Smiers F, Schulz A, Socié G, Vettenranta K, Diaz de Heredia C, Zecca M, Maertens J, Rovira M, Sierra J, Uckan-Cetinkaya D, Skorobogatova E, Antmen AB, Dalle JH, Markiewicz M, Hamladji RM, Kitra-Roussou V, La Nasa G, Kriván G, Al-Seiraihy A, Giardino S, Risitano AM, Peffault de Latour R, Dufour C.

Haematologica. 2019 Jan 24. pii: haematol.2018.206623. doi: 10.3324/haematol.2018.206623. [Epub ahead of print]

4.

Factor H interfers with the adhesion of sickle red cells to vascular endothelium: a novel disease modulating molecule.

Lombardi E, Matte A, Risitano AM, Ricklin D, Lambris JD, De Zanet D, Jokiranta ST, Martinelli N, Scambi C, Salvagno G, Bisoffi Z, Colato C, Siciliano A, Bortolami O, Mazzuccato M, Zorzi F, De Marco L, De Franceschi L.

Haematologica. 2019 Jan 10. pii: haematol.2018.198622. doi: 10.3324/haematol.2018.198622. [Epub ahead of print]

5.

Impact of T-cell depletion strategies on outcomes following hematopoietic stem cell transplantation for idiopathic aplastic anemia: A study on behalf of the European blood and marrow transplant severe aplastic anemia working party.

Samarasinghe S, Clesham K, Iacobelli S, Sbianchi G, Knol C, Hamladji RM, Socié G, Aljurf M, Koh M, Sengeloev H, Dalle JH, Robinson S, Van Lint MT, Halkes CJM, Beelen D, Mufti GJ, Snowden J, Blaise D, de Latour RP, Marsh J, Dufour C, Risitano AM; Severe Aplastic Anaemia Working Party of the EBMT.

Am J Hematol. 2019 Jan;94(1):80-86. doi: 10.1002/ajh.25314. Epub 2018 Nov 25.

PMID:
30328134
6.

Expanding Complement Therapeutics for the Treatment of Paroxysmal Nocturnal Hemoglobinuria.

Mastellos DC, Reis ES, Yancopoulou D, Risitano AM, Lambris JD.

Semin Hematol. 2018 Jul;55(3):167-175. doi: 10.1053/j.seminhematol.2018.02.002. Epub 2018 Feb 14. Review.

PMID:
30032754
7.

Therapeutic complement modulation for hematological diseases: Where we stand and where we are going.

Risitano AM.

Semin Hematol. 2018 Jul;55(3):113-117. doi: 10.1053/j.seminhematol.2018.05.012. Epub 2018 May 29. No abstract available.

PMID:
30032746
8.

Advances in understanding the pathogenesis of acquired aplastic anaemia.

Luzzatto L, Risitano AM.

Br J Haematol. 2018 Sep;182(6):758-776. doi: 10.1111/bjh.15443. Epub 2018 Jul 5. Review.

PMID:
29974931
9.

(Auto-)immune signature in aplastic anemia.

Risitano AM.

Haematologica. 2018 May;103(5):747-749. doi: 10.3324/haematol.2018.190884. No abstract available.

10.

Toward complement inhibition 2.0: Next generation anticomplement agents for paroxysmal nocturnal hemoglobinuria.

Risitano AM, Marotta S.

Am J Hematol. 2018 Aug;93(4):564-577. doi: 10.1002/ajh.25016. Epub 2018 Jan 25.

PMID:
29314145
11.

Combined intensive immunosuppression and eculizumab for aplastic anemia in the context of hemolytic paroxysmal nocturnal hemoglobinuria: a retrospective analysis.

Pagliuca S, Risitano AM, De Fontbrune FS, Robin M, Iori AP, Marotta S, Michonneau D, Villate A, Desmier D, Socié G, De Latour RP.

Bone Marrow Transplant. 2018 Jan;53(1):105-107. doi: 10.1038/bmt.2017.220. Epub 2017 Nov 13. No abstract available.

PMID:
29131151
12.

Transplant results in adults with Fanconi anaemia.

Bierings M, Bonfim C, Peffault De Latour R, Aljurf M, Mehta PA, Knol C, Boulad F, Tbakhi A, Esquirol A, McQuaker G, Sucak GA, Othman TB, Halkes CJM, Carpenter B, Niederwieser D, Zecca M, Kröger N, Michallet M, Risitano AM, Ehninger G, Porcher R, Dufour C; EBMT SAA WP.

Br J Haematol. 2018 Jan;180(1):100-109. doi: 10.1111/bjh.15006. Epub 2017 Nov 2.

PMID:
29094350
13.

Acute immune toxicity during anti-thymocyte globulin: That's CARPA!

Marotta S, Ricci P, Marano L, Beneduce G, Vitagliano O, De Gregorio F, Grimaldi F, Pane F, Risitano AM.

Am J Hematol. 2018 Jan;93(1):E22-E24. doi: 10.1002/ajh.24945. Epub 2017 Nov 3. No abstract available.

14.

Therapeutic outcomes using subcutaneous low dose alemtuzumab for acquired bone marrow failure conditions.

Thota S, Patel BJ, Sadaps M, Balasubramanian S, Sanikommu S, Hirsch C, Marotta S, Sekeres MA, Risitano AM, Maciejewski JP.

Br J Haematol. 2018 Oct;183(1):133-136. doi: 10.1111/bjh.14907. Epub 2017 Sep 14. No abstract available.

PMID:
28905372
15.

Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytes.

Sica M, Rondelli T, Ricci P, De Angioletti M, Risitano AM, Notaro R.

J Hematol Oncol. 2017 Jun 19;10(1):126. doi: 10.1186/s13045-017-0496-x.

16.

Immune insights into AA.

Risitano AM.

Blood. 2017 May 25;129(21):2824-2826. doi: 10.1182/blood-2017-03-771493. No abstract available.

17.

Narrative Based Medicine as a tool for needs assessment of patients undergoing hematopoietic stem cell transplantation.

Gargiulo G, Sansone V, Rea T, Artioli G, Botti S, Continisio GI, Ferri P, Masi D, Risitano AM, Simeone S, La Sala R.

Acta Biomed. 2017 Mar 14;88(1S):18-24. doi: 10.23750/abm.v88i1 -S.6280.

PMID:
28327491
18.

Small-molecule factor D inhibitors targeting the alternative complement pathway.

Maibaum J, Liao SM, Vulpetti A, Ostermann N, Randl S, Rüdisser S, Lorthiois E, Erbel P, Kinzel B, Kolb FA, Barbieri S, Wagner J, Durand C, Fettis K, Dussauge S, Hughes N, Delgado O, Hommel U, Gould T, Mac Sweeney A, Gerhartz B, Cumin F, Flohr S, Schubart A, Jaffee B, Harrison R, Risitano AM, Eder J, Anderson K.

Nat Chem Biol. 2016 Dec;12(12):1105-1110. doi: 10.1038/nchembio.2208. Epub 2016 Oct 24.

PMID:
27775713
19.

Compstatin Cp40 blocks hematin-mediated deposition of C3b fragments on erythrocytes: Implications for treatment of malarial anemia.

Lindorfer MA, Cook EM, Reis ES, Ricklin D, Risitano AM, Lambris JD, Taylor RP.

Clin Immunol. 2016 Oct;171:32-35. doi: 10.1016/j.clim.2016.08.017. Epub 2016 Aug 18.

20.

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

Risitano AM, Marotta S.

Semin Immunol. 2016 Jun;28(3):223-40. doi: 10.1016/j.smim.2016.05.001. Epub 2016 Jun 23. Review.

PMID:
27346521
21.

Paroxysmal nocturnal hemoglobinuria in the era of complement inhibition.

Risitano AM.

Am J Hematol. 2016 Jun;91(4):359-60. doi: 10.1002/ajh.24323. No abstract available.

22.

Assessment of human antihuman antibodies to eculizumab after long-term treatment in patients with paroxysmal nocturnal hemoglobinuria.

Hillmen P, Muus P, Szer J, Hill A, Höchsmann B, Kulasekararaj A, Risitano AM, Van Den Neste E, Liljeholm M, Ebrahim KS, Bedrosian CL, Gao X, Ames D, Socié G.

Am J Hematol. 2016 Mar;91(3):E16-7. doi: 10.1002/ajh.24280. No abstract available.

23.

Twenty years of the Italian Fanconi Anemia Registry: where we stand and what remains to be learned.

Risitano AM, Marotta S, Calzone R, Grimaldi F, Zatterale A; RIAF Contributors.

Haematologica. 2016 Mar;101(3):319-27. doi: 10.3324/haematol.2015.133520. Epub 2015 Dec 3.

24.

Busulfan plus cyclophosphamide versus busulfan plus fludarabine as a preparative regimen for allogeneic haemopoietic stem-cell transplantation in patients with acute myeloid leukaemia: an open-label, multicentre, randomised, phase 3 trial.

Rambaldi A, Grassi A, Masciulli A, Boschini C, Micò MC, Busca A, Bruno B, Cavattoni I, Santarone S, Raimondi R, Montanari M, Milone G, Chiusolo P, Pastore D, Guidi S, Patriarca F, Risitano AM, Saporiti G, Pini M, Terruzzi E, Arcese W, Marotta G, Carella AM, Nagler A, Russo D, Corradini P, Alessandrino EP, Torelli GF, Scimè R, Mordini N, Oldani E, Marfisi RM, Bacigalupo A, Bosi A.

Lancet Oncol. 2015 Nov;16(15):1525-1536. doi: 10.1016/S1470-2045(15)00200-4. Epub 2015 Sep 28.

25.

Eculizumab in Pregnant Patients with Paroxysmal Nocturnal Hemoglobinuria.

Kelly RJ, Höchsmann B, Szer J, Kulasekararaj A, de Guibert S, Röth A, Weitz IC, Armstrong E, Risitano AM, Patriquin CJ, Terriou L, Muus P, Hill A, Turner MP, Schrezenmeier H, Peffault de Latour R.

N Engl J Med. 2015 Sep 10;373(11):1032-9. doi: 10.1056/NEJMoa1502950.

26.

Applying complement therapeutics to rare diseases.

Reis ES, Mastellos DC, Yancopoulou D, Risitano AM, Ricklin D, Lambris JD.

Clin Immunol. 2015 Dec;161(2):225-40. doi: 10.1016/j.clim.2015.08.009. Epub 2015 Sep 1. Review.

27.

Similar outcome of upfront-unrelated and matched sibling stem cell transplantation in idiopathic paediatric aplastic anaemia. A study on behalf of the UK Paediatric BMT Working Party, Paediatric Diseases Working Party and Severe Aplastic Anaemia Working Party of EBMT.

Dufour C, Veys P, Carraro E, Bhatnagar N, Pillon M, Wynn R, Gibson B, Vora AJ, Steward CG, Ewins AM, Hough RE, de la Fuente J, Velangi M, Amrolia PJ, Skinner R, Bacigalupo A, Risitano AM, Socie G, Peffault de Latour R, Passweg J, Rovo A, Tichelli A, Schrezenmeier H, Hochsmann B, Bader P, van Biezen A, Aljurf MD, Kulasekararaj A, Marsh JC, Samarasinghe S.

Br J Haematol. 2015 Nov;171(4):585-94. doi: 10.1111/bjh.13614. Epub 2015 Jul 28.

PMID:
26223288
28.

Complement C3dg-mediated erythrophagocytosis: implications for paroxysmal nocturnal hemoglobinuria.

Lin Z, Schmidt CQ, Koutsogiannaki S, Ricci P, Risitano AM, Lambris JD, Ricklin D.

Blood. 2015 Aug 13;126(7):891-4. doi: 10.1182/blood-2015-02-625871. Epub 2015 Jun 16.

29.

Current and future pharmacologic complement inhibitors.

Risitano AM.

Hematol Oncol Clin North Am. 2015 Jun;29(3):561-82. doi: 10.1016/j.hoc.2015.01.009. Epub 2015 Apr 4. Review.

PMID:
26043392
30.

Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention.

Mastellos DC, Yancopoulou D, Kokkinos P, Huber-Lang M, Hajishengallis G, Biglarnia AR, Lupu F, Nilsson B, Risitano AM, Ricklin D, Lambris JD.

Eur J Clin Invest. 2015 Apr;45(4):423-40. doi: 10.1111/eci.12419. Epub 2015 Mar 9. Review.

31.

Dissecting complement blockade for clinic use.

Risitano AM.

Blood. 2015 Jan 29;125(5):742-4. doi: 10.1182/blood-2014-12-616300.

32.

Hematopoietic stem cell transplantation for aplastic anemia and paroxysmal nocturnal hemoglobinuria: current evidence and recommendations.

Marotta S, Pagliuca S, Risitano AM.

Expert Rev Hematol. 2014 Dec;7(6):775-89. doi: 10.1586/17474086.2014.967678. Epub 2014 Oct 21. Review.

PMID:
25331515
33.

Role of lenalidomide in the management of myelodysplastic syndromes with del(5q) associated with pure red cell aplasia (PRCA).

Cerchione C, Catalano L, Cerciello G, Avilia S, Picardi M, Risitano AM, Pisano I, Alfinito F, Pane F.

Ann Hematol. 2015 Mar;94(3):531-4. doi: 10.1007/s00277-014-2192-z. Epub 2014 Aug 20. No abstract available.

PMID:
25135452
34.

Outcome of aplastic anemia in adolescence: a survey of the Severe Aplastic Anemia Working Party of the European Group for Blood and Marrow Transplantation.

Dufour C, Pillon M, Passweg J, Socié G, Bacigalupo A, Franceschetto G, Carraro E, Oneto R, Risitano AM, Peffault de Latour R, Tichelli A, Rovo A, Peters C, Hoechsmann B, Samarasinghe S, Kulasekararaj AG, Schrezenmeier H, Aljurf M, Marsh J.

Haematologica. 2014 Oct;99(10):1574-81. doi: 10.3324/haematol.2014.106096. Epub 2014 Aug 1.

35.
36.

Immunological derangement in hypocellular myelodysplastic syndromes.

Serio B, Risitano A, Giudice V, Montuori N, Selleri C.

Transl Med UniSa. 2014 Feb 4;8:31-42. eCollection 2014 Jan.

37.
38.

Incidence and outcome of invasive fungal diseases after allogeneic stem cell transplantation: a prospective study of the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

Girmenia C, Raiola AM, Piciocchi A, Algarotti A, Stanzani M, Cudillo L, Pecoraro C, Guidi S, Iori AP, Montante B, Chiusolo P, Lanino E, Carella AM, Zucchetti E, Bruno B, Irrera G, Patriarca F, Baronciani D, Musso M, Prete A, Risitano AM, Russo D, Mordini N, Pastore D, Vacca A, Onida F, Falcioni S, Pisapia G, Milone G, Vallisa D, Olivieri A, Bonini A, Castagnola E, Sica S, Majolino I, Bosi A, Busca A, Arcese W, Bandini G, Bacigalupo A, Rambaldi A, Locasciulli A.

Biol Blood Marrow Transplant. 2014 Jun;20(6):872-80. doi: 10.1016/j.bbmt.2014.03.004. Epub 2014 Mar 14.

39.

Peptide inhibitors of C3 activation as a novel strategy of complement inhibition for the treatment of paroxysmal nocturnal hemoglobinuria.

Risitano AM, Ricklin D, Huang Y, Reis ES, Chen H, Ricci P, Lin Z, Pascariello C, Raia M, Sica M, Del Vecchio L, Pane F, Lupu F, Notaro R, Resuello RR, DeAngelis RA, Lambris JD.

Blood. 2014 Mar 27;123(13):2094-101. doi: 10.1182/blood-2013-11-536573. Epub 2014 Feb 4. Erratum in: Blood. 2017 Apr 13;129(15):2205.

40.

Selective strong synergism of Ruxolitinib and second generation tyrosine kinase inhibitors to overcome bone marrow stroma related drug resistance in chronic myelogenous leukemia.

Quintarelli C, De Angelis B, Errichiello S, Caruso S, Esposito N, Colavita I, Raia M, Pagliuca S, Pugliese N, Risitano AM, Picardi M, Luciano L, Saglio G, Martinelli G, Pane F.

Leuk Res. 2014 Feb;38(2):236-42. doi: 10.1016/j.leukres.2013.11.006. Epub 2013 Nov 15.

PMID:
24280282
41.

Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Rondelli T, Risitano AM, Peffault de Latour R, Sica M, Peruzzi B, Ricci P, Barcellini W, Iori AP, Boschetti C, Valle V, Frémeaux-Bacchi V, De Angioletti M, Socie G, Luzzatto L, Notaro R.

Haematologica. 2014 Feb;99(2):262-6. doi: 10.3324/haematol.2013.090001. Epub 2013 Sep 13.

42.

Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria.

Hillmen P, Muus P, Röth A, Elebute MO, Risitano AM, Schrezenmeier H, Szer J, Browne P, Maciejewski JP, Schubert J, Urbano-Ispizua A, de Castro C, Socié G, Brodsky RA.

Br J Haematol. 2013 Jul;162(1):62-73. doi: 10.1111/bjh.12347. Epub 2013 Apr 25.

43.

Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.

Schmidt CQ, Bai H, Lin Z, Risitano AM, Barlow PN, Ricklin D, Lambris JD.

J Immunol. 2013 Jun 1;190(11):5712-21. doi: 10.4049/jimmunol.1203548. Epub 2013 Apr 24.

44.
45.

Alternative immunosuppression in patients failing immunosuppression with ATG who are not transplant candidates: Campath (Alemtuzumab).

Risitano AM, Schrezenmeier H.

Bone Marrow Transplant. 2013 Feb;48(2):186-90. doi: 10.1038/bmt.2012.245. Epub 2012 Dec 10. Review.

PMID:
23222381
46.

Paroxysmal nocturnal hemoglobinuria and other complement-mediated hematological disorders.

Risitano AM.

Immunobiology. 2012 Nov;217(11):1080-7. doi: 10.1016/j.imbio.2012.07.014. Review.

PMID:
22964233
47.

The complement receptor 2/factor H fusion protein TT30 protects paroxysmal nocturnal hemoglobinuria erythrocytes from complement-mediated hemolysis and C3 fragment.

Risitano AM, Notaro R, Pascariello C, Sica M, del Vecchio L, Horvath CJ, Fridkis-Hareli M, Selleri C, Lindorfer MA, Taylor RP, Luzzatto L, Holers VM.

Blood. 2012 Jun 28;119(26):6307-16. doi: 10.1182/blood-2011-12-398792. Epub 2012 May 10.

48.

From perpetual haemosiderinuria to possible iron overload: iron redistribution in paroxysmal nocturnal haemoglobinuria patients on eculizumab by magnetic resonance imaging.

Risitano AM, Imbriaco M, Marando L, Seneca E, Soscia E, Malcovati L, Iori AP, Pane F, Notaro R, Matarazzo M.

Br J Haematol. 2012 Aug;158(3):415-8. doi: 10.1111/j.1365-2141.2012.09145.x. Epub 2012 May 10. No abstract available.

PMID:
22571809
49.

Prospective study of rabbit antithymocyte globulin and cyclosporine for aplastic anemia from the EBMT Severe Aplastic Anaemia Working Party.

Marsh JC, Bacigalupo A, Schrezenmeier H, Tichelli A, Risitano AM, Passweg JR, Killick SB, Warren AJ, Foukaneli T, Aljurf M, Al-Zahrani HA, Höchsmann B, Schafhausen P, Roth A, Franzke A, Brummendorf TH, Dufour C, Oneto R, Sedgwick P, Barrois A, Kordasti S, Elebute MO, Mufti GJ, Socie G; European Blood and Marrow Transplant Group Severe Aplastic Anaemia Working Party.

Blood. 2012 Jun 7;119(23):5391-6. doi: 10.1182/blood-2012-02-407684. Epub 2012 Apr 27. Erratum in: Blood. 2013 Jun 20;121(25):5104. Höchsmann, Britta [added].

50.

Multicenter experience using total lymphoid irradiation and antithymocyte globulin as conditioning for allografting in hematological malignancies.

Messina G, Giaccone L, Festuccia M, Irrera G, Scortechini I, Sorasio R, Gigli F, Passera R, Cavattoni I, Filippi AR, Schianca FC, Pini M, Risitano AM, Selleri C, Levis A, Mordini N, Gallamini A, Pastano R, Casini M, Aglietta M, Montanari M, Console G, Boccadoro M, Ricardi U, Bruno B; Gruppo Italiano Trapianti di Midollo.

Biol Blood Marrow Transplant. 2012 Oct;18(10):1600-7. doi: 10.1016/j.bbmt.2012.03.012. Epub 2012 Apr 5.

Supplemental Content

Loading ...
Support Center